Oppenheimer analyst Jay Olson maintained a Buy rating on CymaBay Therapeutics (CBAY) yesterday. The company’s shares closed on Friday at $11.93.
According to TipRanks.com, Olson is ranked 0 out of 5 stars with an average return of -6.1% and a 39.3% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.
CymaBay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20.43, a 71.2% upside from current levels. In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $20 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15 and a one-year low of $6.31. Currently, CymaBay Therapeutics has an average volume of 700.4K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is negative on the stock. Last month, Carl Goldfischer, a Director at CBAY sold 11,675 shares for a total of $105,309.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
